Employers pick their own contribution toward semaglutide shots or pills. AJMC notes WTW found GLP-1 weight loss coverage fell to 53% of employers, the first drop in three years.
Recap by typeshit. Full story at The American Journal of Managed Care.
Health minister Dzulkefly says the government did not set aside dedicated 2026 budget funds for the two GLP-1 treatments.
Sales missed forecasts by about $33 million, but Lilly says demand more than tripled. Novo's Wegovy pill still holds roughly 75% of oral GLP-1 scripts.
Volume rose 53% while prices dropped, a sign cheaper access is pulling in patients. Breakdown covers LillyDirect pricing, the $50 Medicare Bridge and Novo's 2027 cuts.
Korea's first homegrown GLP-1 obesity drug, efpeglenatide, comes in about 25% below Wegovy and 40% below Mounjaro for its first four weeks.
The obesity doctor responds to a pharmacist who claims to expose the truth about GLP-1s. Tap through to see where he agrees and where he pushes back.
8:11
A peptide-focused creator runs through retatrutide side effects aimed at men. Her claims aren't backed by sources given, so treat them as her take.
Loading…